BR112017008664A2 - ligando 2 do receptor canabinóide radiomarcado - Google Patents
ligando 2 do receptor canabinóide radiomarcadoInfo
- Publication number
- BR112017008664A2 BR112017008664A2 BR112017008664A BR112017008664A BR112017008664A2 BR 112017008664 A2 BR112017008664 A2 BR 112017008664A2 BR 112017008664 A BR112017008664 A BR 112017008664A BR 112017008664 A BR112017008664 A BR 112017008664A BR 112017008664 A2 BR112017008664 A2 BR 112017008664A2
- Authority
- BR
- Brazil
- Prior art keywords
- ligand
- cannabinoid receptor
- radiolabelled
- radiolabelled cannabinoid
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/40—Acylated on said nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/948—Sedatives, e.g. cannabinoids, barbiturates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Optics & Photonics (AREA)
- Cardiology (AREA)
- Anesthesiology (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
Abstract
a presente invenção refere-se a um composto de fórmula (i) (i) em que r1 é tal como se encontra definido na descrição e nas reivindicações. o composto de fórmula (i) pode ser usado como um ligando radio marcado
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14190523 | 2014-10-27 | ||
PCT/EP2015/074557 WO2016066534A1 (en) | 2014-10-27 | 2015-10-23 | Radiolabeled cannabinoid receptor 2 ligand |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112017008664A2 true BR112017008664A2 (pt) | 2018-01-30 |
Family
ID=51870829
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017008664A BR112017008664A2 (pt) | 2014-10-27 | 2015-10-23 | ligando 2 do receptor canabinóide radiomarcado |
Country Status (10)
Country | Link |
---|---|
US (1) | US10227308B2 (pt) |
EP (1) | EP3212241B1 (pt) |
JP (1) | JP6637034B2 (pt) |
KR (1) | KR20170072876A (pt) |
CN (1) | CN106795121A (pt) |
BR (1) | BR112017008664A2 (pt) |
CA (1) | CA2956056A1 (pt) |
MX (1) | MX2017002015A (pt) |
RU (1) | RU2017116665A (pt) |
WO (1) | WO2016066534A1 (pt) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3212241B1 (en) | 2014-10-27 | 2019-05-08 | F. Hoffmann-La Roche AG | Radiolabeled cannabinoid receptor 2 ligand |
EP3995155A1 (en) * | 2018-06-27 | 2022-05-11 | F. Hoffmann-La Roche AG | Radiolabeled cannabinoid receptor 2 ligand |
CN109091681B (zh) * | 2018-08-09 | 2021-08-03 | 中山大学附属第一医院 | [18f]三氟甲基含硫氨基酸类pet显像剂及其制备方法和应用 |
EP4016069A1 (en) * | 2020-12-21 | 2022-06-22 | F. Hoffmann-La Roche AG | Sensor device and method of its use |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008141239A1 (en) * | 2007-05-10 | 2008-11-20 | Acadia Pharmaceuticals Inc. | Imidazol [1,2-a] pyridines and related compounds with activity at cannabinoid cb2 receptors |
CN102216277A (zh) * | 2008-09-16 | 2011-10-12 | 雅培制药有限公司 | 作为大麻素受体配体的被取代的苯甲酰胺 |
WO2011061744A2 (en) | 2009-11-19 | 2011-05-26 | Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. | Novel arylated camphenes, processes for their preparation and uses thereof |
EP3212241B1 (en) | 2014-10-27 | 2019-05-08 | F. Hoffmann-La Roche AG | Radiolabeled cannabinoid receptor 2 ligand |
-
2015
- 2015-10-23 EP EP15784679.1A patent/EP3212241B1/en not_active Not-in-force
- 2015-10-23 WO PCT/EP2015/074557 patent/WO2016066534A1/en active Application Filing
- 2015-10-23 JP JP2017514901A patent/JP6637034B2/ja not_active Expired - Fee Related
- 2015-10-23 MX MX2017002015A patent/MX2017002015A/es unknown
- 2015-10-23 KR KR1020177008551A patent/KR20170072876A/ko unknown
- 2015-10-23 BR BR112017008664A patent/BR112017008664A2/pt not_active Application Discontinuation
- 2015-10-23 CA CA2956056A patent/CA2956056A1/en not_active Abandoned
- 2015-10-23 RU RU2017116665A patent/RU2017116665A/ru not_active Application Discontinuation
- 2015-10-23 CN CN201580046629.2A patent/CN106795121A/zh active Pending
-
2017
- 2017-02-27 US US15/443,894 patent/US10227308B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP3212241A1 (en) | 2017-09-06 |
JP2017534580A (ja) | 2017-11-24 |
CA2956056A1 (en) | 2016-05-06 |
RU2017116665A3 (pt) | 2019-04-23 |
US20170166534A1 (en) | 2017-06-15 |
KR20170072876A (ko) | 2017-06-27 |
CN106795121A (zh) | 2017-05-31 |
RU2017116665A (ru) | 2018-11-29 |
WO2016066534A1 (en) | 2016-05-06 |
US10227308B2 (en) | 2019-03-12 |
MX2017002015A (es) | 2017-09-01 |
EP3212241B1 (en) | 2019-05-08 |
JP6637034B2 (ja) | 2020-01-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CU20170172A7 (es) | 4,6-diaminoquinolin-3-carbonitrilos sustituidos útiles como agentes analgésicos, antipiréticos o antiinflamatorios y antineoplásicos | |
BR112016002391A2 (pt) | composições tópicas e métodos de uso das mesmas | |
BR112015009600A2 (pt) | piridina-2-amidas úteis como agonistas cb2 | |
CR20150634A (es) | Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina | |
BR112015020795A2 (pt) | derivados de pirazol novos | |
UY35469A (es) | Moduladores de p2x7 | |
CR20160272A (es) | REGULADORES DE Nrf2 | |
CR20150541A (es) | Compuestos y composiciones nuevos para la inhibición de fasn | |
CR20150277A (es) | Piridina-2-amidas utiles como agonistas cb2 | |
BR112017000456A2 (pt) | composições antivirais tópicas e métodos de uso das mesmas | |
PH12015502471A1 (en) | Purine derivatives as cb2 receptor agonists | |
UY34636A (es) | Composiciones tópicas que comprenden fipronilo y permetrina y sus métodos de uso | |
CR20150440A (es) | Nuevos derivados de piridina | |
MX2015011297A (es) | Uso de polipropilenimina alcoxilada para el cuidado de la ropa y composiciones para ello. | |
BR112015008117A2 (pt) | benzamidas | |
PH12016501865A1 (en) | Pyridine-2-amides useful as cb2 agonists | |
EA201691982A1 (ru) | 5,6-дизамещенные пиридин-2-карбоксамиды в качестве агонистов каннабиноидных рецепторов | |
ITMI20130942A1 (it) | Pianificazione dell'esecuzione di attivita' con risoluzione di dipendenze | |
BR112017008664A2 (pt) | ligando 2 do receptor canabinóide radiomarcado | |
BR112016028022A2 (pt) | compostos de sulfonamida e seus usos como inibidores de stat5 | |
DOP2016000021A (es) | Imidazotiazol sulfonamidas como nematicidas | |
CY1121116T1 (el) | Νεα μεθοδος για την συνθεση αγομελατινης | |
CL2015002389A1 (es) | Composiciones herbicidas que contienen isoxabena y flufenaceto. | |
BR112015030824A2 (pt) | novos derivados de tetrazolona | |
CL2016001608A1 (es) | Composición de fijación del suelo que contiene de óxido de hierro (iii) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notice of approval relating to section 229 industrial property law | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: suspension of the patent application procedure | ||
B08F | Application fees: dismissal - article 86 of industrial property law |
Free format text: REFERENTE A 5A ANUIDADE. |
|
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |